The Third International Congress on Cardiac Problems in Pregnancy was held in Venice, Italy on 20-23 February 2014. In the UNESCO world heritage site, several hundred physicians and health care providers gathered to feast on a banquet of knowledge and ideas exchanged over two and a half days of presentations.
The congress began with some of the known concepts in the assessment of pregnant women with cardiac issues, and the importance of team collaborative approach to the management of these patients during pregnancy and delivery. The emerging role of brain naturetic peptide as a tool for assessing and predicting cardiac deterioration in these patients was discussed and certainly represents a potential means for monitoring these patients during pregnancy.
This contrasted with the as yet unresolved issues surrounding the appropriate anticoagulation strategy for pregnant women with prosthetic heart valves. The debate on whether every woman who needs a valve replacement receives a bio-prosthetic valve may have ended on a 'technical tie'; we unanimously and respectfully declare that the clear winner was in the fact one-of-our-own who argued against this! An updated report from ROPAC, the Registry of Pregnancy and Cardiac disease which began in 2007 and is collecting data from 30 nations, was presented. It provided further data to guide management of these women with regard to mode of delivery, impact of cardiac medications, heart failure and arrhythmia. The findings indicate that most of these women have excellent outcomes -except for those with pre-existing cardiomyopathy or prosthetic heart valves. In addition, findings from the registry affirm that delivery by Caesarean section conferred no benefit to the mother and increases risks for the baby.
Further evidence was presented by Drs Thomas Easterling and Gideon Koren regarding altered pharmacokinetics for many medications during pregnancy as well as the safety of 'required' drugs during pregnancy. In brief, significant increases in dosing for such medications as beta-blockers may be required during pregnancy, and both angiotensin-converting enzyme (ACE) inhibitors and selective serotonin reuptake inhibitors (SSRIs) are highly unlikely to lead to increased cardiac defects in babies, if used in the first trimester.
The meeting closed with a tantalising discussion on peripartum cardiomyopathy (PPCM) and its possible pathophysiology and treatment. Is there a separate 'pre-eclamptic cardiomyopathy' that has a much more benign outcome? Are some PPCM cases simply an unmasking of a genetic/familial cardiomyopathy and hence demonstrate a poorer prognosis? Is prolactin suppression with bromocriptine a solution? Perhaps, these answers will be forthcoming by the next conference.
An international conference such as this, in a field close to our hearts, was again a reminder of the different practice patterns for similar medical issues around the globe. It was enlightening to contrast the different approaches and realities faced by those with limitless versus minimal resources; from centres with easy access to magnetic resonance imaging serving populations where rheumatic heart disease is virtually non-existent to those relying only on superb clinical skills and acumen in resource-starved nations. We are all wiser after we have shared this knowledge and begin our conversations. 
In this issue
In this issue we have a diabetes and obesity theme running through many of the articles. Naomi Achong and colleagues review the factors determining insulin requirements in women with type 1 diabetes in pregnancy. Minoli Vinoda Abeysekera and colleagues review techniques to measure free-living energy expenditure during pregnancy and Charmaine Wright and co-workers use a large database to analyze obesity, gestational weight gain and parity as risk factors for developing carpal tunnel syndrome in pregnancy. Cynthia Battle and Margaret Howard reflect on mother and baby psychiatric day hospitals and there are two evaluations of important areas of clinical practice from Canada; Erica Wang and colleagues assessed haemorrhagic complications of peripartum anticoagulation and Nadine Sauve and co-workers looked at the use of magnesium sulfate for eclampsia prevention in their tertiary centre.
